Suppr超能文献

鉴定 HPr 激酶/磷酸酶抑制剂:针对耐药粪肠球菌的新型抗菌药物。

Identification of HPr kinase/phosphorylase inhibitors: novel antimicrobials against resistant Enterococcus faecalis.

机构信息

Animal Biochemistry Division, National Dairy Research Institute, Karnal, Haryana, India.

Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Biochemistry, Åbo Akademi University, 20520, Turku, Finland.

出版信息

J Comput Aided Mol Des. 2022 Jul;36(7):507-520. doi: 10.1007/s10822-022-00461-6. Epub 2022 Jul 9.

Abstract

Enterococcus faecalis, a gram-positive bacterium, is among the most common nosocomial pathogens due to its limited susceptibility to antibiotics and its reservoir of the genes coding for virulence factors. Bacterial enzymes such as kinases and phosphorylases play important roles in diverse functions of a bacterial cell and, thus, are potential antibacterial drug targets. In Gram-positive bacteria, HPr Kinase/Phosphorylase (HPrK/P), a bifunctional enzyme is involved in the regulation of carbon catabolite repression by phosphorylating/dephosphorylating the histidine-containing phosphocarrier protein (HPr) at Ser46 residue. Deficiencies in HPrK/P function leads to severe defects in bacterial growth. This study aimed at identifying novel inhibitors of E. faecalis HPrK/P from a commercial compound library using structure-based virtual screening. The hit molecules were purchased and their effect on enzyme activity and growth of resistant E. faecalis was evaluated in vitro. Furthermore, docking and molecular dynamics simulations were performed to study the interactions of the hit compounds with HPrK/P. Among the identified hit molecules, two compounds inhibited the phosphorylation of HPr as well as significantly reduced the growth of resistant E. faecalis in vitro. These identified potential HPrK/P inhibitors open new research avenues towards the development of novel antimicrobials against resistant Gram-positive bacteria.

摘要

粪肠球菌是一种革兰氏阳性菌,由于其对抗生素的敏感性有限,并且具有编码毒力因子的基因库,因此是最常见的医院获得性病原体之一。细菌酶,如激酶和磷酸酶,在细菌细胞的各种功能中发挥重要作用,因此是潜在的抗菌药物靶点。在革兰氏阳性菌中,HPr 激酶/磷酸酶(HPrK/P)是一种双功能酶,通过磷酸化/去磷酸化组氨酸残基 46 位的含磷酸载体蛋白(HPr)参与碳分解代谢物阻遏的调节。HPrK/P 功能的缺失导致细菌生长严重缺陷。本研究旨在从商业化合物库中通过基于结构的虚拟筛选鉴定粪肠球菌 HPrK/P 的新型抑制剂。购买了命中分子,并在体外评估它们对耐药粪肠球菌酶活性和生长的影响。此外,还进行了对接和分子动力学模拟,以研究命中化合物与 HPrK/P 的相互作用。在鉴定出的命中分子中,有两种化合物抑制了 HPr 的磷酸化,并且显著降低了耐药粪肠球菌在体外的生长。这些鉴定出的潜在 HPrK/P 抑制剂为开发针对耐药革兰氏阳性菌的新型抗菌药物开辟了新的研究途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c8c/9399212/27bc1e4908dd/10822_2022_461_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验